Back to News
Market Impact: 0.32
CAPR Investor Reminder: Capricor Therapeutics Securities Fraud Class Action after 64% Stock Drop is Pending – Investors Notified to Contact BFA Law before September 28 Deadline
Source: businesswire.com
Legal & LitigationHealthcare & Biotech
Capricor Therapeutics faces a pending securities-fraud class action after its stock fell 64%. BFA Law notified investors of a September 28 deadline to contact the firm, creating material legal and reputational risk for the biotech company.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly negative
Sentiment Score
-0.72
Ticker Sentiment
CAPR-0.95
More News
- California AG Says Paramount-WBD Merger Would Hurt the State
- Microsoft exec called AI scraping the “largest theft of labor in human history”
- EPA immediately sued over plans to repeal climate rules for power plants
- Jana Partners pushes Cooper to replace CEO, weigh asset sales- WSJ
- UN fact-finding mission says US committed possible war crimes in Iran
- Halozyme prices $1.3 billion convertible notes offering
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- State of M&A and Private Markets, June 2026: A $4.9 Trillion Rebound, Underwritten on Money That Never Got Cheaper
- Run Cost-Controlled Financial Research in AllMind Agent Studio